SCHEMBL254990

SCHEMBL254990

CC(C)C1CC(CO)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10216419 1.00
SCHEMBL10216587 1.00
SCHEMBL19007018 0.97 EPHX2 (0.38)
SCHEMBL12418401 0.82 OPRM1 (0.34)
SCHEMBL12418402 0.82 OPRM1 (0.34)
SCHEMBL25009658 0.82 OPRM1 (0.34)
SCHEMBL13313072 0.82 OPRM1 (0.34)
SCHEMBL12418400 0.82 OPRM1 (0.34)
SCHEMBL10094034 0.82 OPRM1 (0.34)
SCHEMBL21907221 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 EP disclosed
US-20240317706-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-26 US disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 WO disclosed
US-20230373952-A1 LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC 2023-11-23 US disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 US disclosed
US-11713312-B2 Substituted bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2023069720-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
US-10683280-B2 Chemokine receptor modulators and uses thereof RAPT THERAPEUTICS, INC. (US) 2020-06-16 US disclosed
US-20190233397-A1 CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF RAPT THERAPEUTICS, INC. 2019-08-01 US disclosed
US-20170158703-A9 METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-06-08 US disclosed
US-9669027-B2 Hepatitis C virus inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-06-06 US disclosed
US-9546153-B2 Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2017-01-17 US disclosed
US-20160289236-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2016-10-06 US disclosed
EP-3042906-A1 METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-07-13 EP disclosed
US-20160194331-A1 METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-07-07 US disclosed
US-20150274696-A1 BICYCLIC HETEROCYCLE SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2015-10-01 US disclosed
US-20120055674-A1 DETECTING AND CORRECTING UNINTENDED FLUID FLOW BETWEEN SUBTERRANEAN ZONES LANDMARK GRAPHICS CORPORATION (US) 2012-03-08 US disclosed